Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2008

View Archived Issues

INNO-406 well tolerated in patients with advanced leukemia

Clinuvel to commence phase II CUV-1647 trials in solar urticaria

Symphogen collaborates with Genentech for antibody therapeutics

Novel agents for skin wrinkling reported by Lipotec

Apixaban begins new phase III trial in VTE

Patient enrollment begins in Reolysin phase I/II ovarian cancer trial

Avant announces research collaborations with 3M

Biovest reports blinded data from pivotal BiovaxID trial

Compugen discovers novel drug targets for cancer antibody therapeutics

Targacept and AstraZeneca evaluate AZD-3480 in phase II adult ADHD trial

Antiosteoporotic potential of denosumab evaluated in phase III studies

Phase II results with AstraZeneca's endothelin receptor antagonist ZD-4054 presented

Giripladib reduces joint destruction in mouse models of rheumatoid arthritis

Cytotoxic T-cell responses achieved with IMP-321 treatment in metastatic breast cancer patients

Pain and King submit NDA for Remoxy for moderate to severe pain

ApoCell to detect innovative biomarkers in phase II RTA-402 trial

Maxygen receives U.K. approval to initiate phase I trial of Maxy-VII for hemophilia

Morria receives South African regulatory approval to initiate phase II study of MRX-4 in AR

Duska licenses portfolio of heart failure drugs from Duke and Johns Hopkins universities

Generex initiates dosing in phase III clinical trial of oral insulin spray Generex Oral-lyn

Oncothyreon doses first patient in phase Ib PX-12 advanced metastatic cancer trial

Novo Nordisk discontinues phase III NovoSeven trial in trauma patients

Opexa reports positive 2-year data from phase I/II Tovaxin studies

BioWa licenses Potelligent technology to Novartis for antibody research

Lytix plans to initiate clinical trials for anticancer molecule Oncopore

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...